{
  "id": 20594581,
  "title": "Q32 Bio at Jefferies Global Healthcare Conference: phase iii push",
  "url": "https://urgent.news/2026/11/18/q32-bio-at-jefferies-global-healthcare-conference-phase-iii-push",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-18T12:34:27.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/transcripts/q32-bio-at-jefferies-global-healthcare-conference-phase-iii-push-93CH-5035814"
  },
  "original_language": "en",
  "account": "On Wednesday, November 18, 2026, Q32 Bio took the stage at the Jefferies Global Healthcare Conference to share its roadmap for the lead immunology drug, bempikibart, in the treatment of alopecia areata. The company unveiled plans for a Phase III study, contingent on final alignment with the FDA on trial design. Management highlighted promising Phase II data, showing response rates between 30% and 40%, and affirmed its financial readiness, boasting nearly $300 million in cash reserves. CEO Jodie Morrison emphasized the competitive landscape and the importance of a swift trial to bring the drug to patients quickly. The pivotal study is projected to enroll around 850 patients, with enrollment anticipated in the first half of 2027 across North America, Europe, and select Asia-Pacific regions. The primary endpoint of week 36 is seen as a potential advantage over competitors with longer study durations. Q32 Bio is also exploring new indications, such as vitiligo, lichen planus, rheumatoid arthritis, celiac disease, and eosinophilic esophagitis. Management is finalizing the study protocol and actively discussing design options with the FDA.",
  "summary": null,
  "key_points": [
    "Q32 Bio presented Phase III plans for bempikibart at Jefferies Global Healthcare Conference.",
    "Phase II data showed response rates between 30% and 40% for alopecia areata treatment.",
    "Company has $300 million in cash reserves, plans 850-patient trial starting H2 2027."
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}